Chromosomal region 2q33 encodes the immune regulatory genes, CTLA4, ICOS and CD28, which are involved in regulation of T-cell activity and has been studied as a candidate gene locus in autoimmune diseases, including coeliac disease (CD). We have investigated whether an association exists between this region and CD in the Irish population using a comprehensive analysis for genetic variation. Using a haplotype-tagging approach, this gene cluster was investigated for disease association in a case-control study comprising 394 CD patients and 421 ethnically matched healthy controls. Several SNPs, including CTLA4_CT60, showed association with disease; however, after correction for multiple-testing, CTLA4À658C/T was the only polymorphism found to show significant association with disease when allele, genotype, or carrier status frequency were analysed (carrier status (Allele C), P ¼ 0.0016). Haplotype analysis revealed a haplotype incorporating the CD28/CTLA4 and two 5 0 ICOS polymorphisms to be significantly associated with disease (patients 24.1%; controls 31.5%; P ¼ 0.035), as was a shorter haplotype composed of the CTLA4 markers only (30.9 vs 34.9%; P ¼ 0.042). The extended haplotype incorporating CD28/CTLA4 and 5 0 ICOS is more strongly associated with disease than haplotypes of individual genes. This suggests a causal variant associated with this haplotype may be associated with disease in this population.
Introduction
Coeliac disease (CD) is an inflammatory disorder characterised by villous atrophy of the small intestinal mucosa. It results from an immunological response to ingested wheat gluten or related proteins from barley and rye in susceptible individuals. 1 The incidence of CD has been approximated at less than 1 in 100 to 1 in 300 in a variety of European populations. 2 Results from familial and twins studies show that CD susceptibility is a genetic trait with a complex pattern of inheritance, indicating that several genetic factors are involved in disease susceptibility. 3 An association between CD and the HLA genes of the major histocompatibility complex on chromosome 6p21 has been established. The HLA-DQA1*05 and DQB1*02 alleles are found in the majority of CD patients. 4 Evidence for other MHC-encoded risk genes also exists. 5, 6 Overall, the contribution of the HLA region to the development of CD among siblings has been estimated to be about 30%, [7] [8] [9] [10] thus implying that non-HLA genes are at least as important in predisposing to disease. To date, a number of genomic regions have been identified as harbouring genes involved in CD susceptibility. Among those with the greatest body of evidence supporting association are the CELIAC2 locus on chromosome 5 [11] [12] [13] [14] and the CELIAC3 region on chromosome 2q33. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Chromosome region 2q33 (CELIAC3) contains the CD28, cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and inducible costimulator (ICOS) genes, all of which are important regulators of T-cell activity. CD28 and ICOS are involved in T-cell activation while CTLA4 is a negative regulator of activation, as it competes with CD28 for the same receptors, CD80 and CD86. 26 This implicates these genes as potential factors in autoimmune disease, and makes this region an interesting candidate area for investigation.
A number of other autoimmune diseases have previously been associated with genetic variation at CTLA4, for example, type 1 diabetes (T1D), 27 multiple sclerosis (MS) 28 and Graves disease (GD). 29 Association between markers within or near the CTLA4 gene and CD have been observed in a number of different populations, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] while other studies have failed to find any association between CTLA4 and disease. [30] [31] [32] [33] [34] Linkage studies have also shown conflicting results, with evidence for, 17, 21, 23 and against 30, 31 observed in different populations. A large European study 35 recently observed nominally significant linkage and association to disease but were unable to conclusively identify the primary functional gene variant. However, multiple replications of association or linkage findings between the CTLA4 region and disease suggest that this is a genuine disease susceptibility locus.
A recent comprehensive investigation of the 2q33 region, which incorporated 108 SNPs, identified the primary association with a number of autoimmune diseases to be the CT60 ( þ 6230G/A) polymorphism. 36 A number of studies have investigated CT60 for an association with CD. Results reveal a borderline significant association in two populations 15, 24 and no association in three others. 23, 33, 34 Few studies have investigated the association between CD28 and ICOS single-nucleotide polymorphisms and CD. 24, 34 A putative association was observed between four ICOS SNPs and disease in one population. 34 In this study, we have used a haplotype-tagging approach formulated from previous studies of genetic variation in the 2q33 region to investigate whether an association exists between this region and CD. We selected previously identified haplotype-tagging SNPs (htSNPs) in CTLA4, 37 and generated our own htSNPs in the ICOS gene using haplotype data previously published. 38 We also selected three SNPs in CD28 based on their location to obtain a haplotype that will incorporate a large section of the gene. Haplotype tagging SNPs were combined with several others in CTLA4 and ICOS, which have previously either been associated with disease or have possible functional genetic effects, thus allowing a comprehensive study of the region with the ability to detect all common haplotypes as previously defined for CTLA4 and ICOS. Our data demonstrate that there is a significant association between CD susceptibility and a haplotype extending from ICOS to CD28 on chromosome 2q33.
Results
All polymorphic sites were analysed for allelic, genotypic and carrier status association with disease individually and results are listed in Tables 1 and 2 (which  reports significantly A permutation analysis, using the minimum P-value across all SNPs as the test statistic, was used to allow for multiple testing and to assess the overall significance of the association between SNPs and disease (described in the Methods section). There was a significant association between carrier status and CD; only 58 of the 5000 simulations (1.16%) yielded a minimum P-value less than that for the observed data. The association between genotype and disease was also statistically significant with 227 of the 5000 simulations (4.52%) yielding a test statistic less than the observed data test statistic. The CTLA4À658 C allele carrier status was the only polymorphism with a P-value below the corresponding 5th percentile for the permutations (0.0069 for carrier status and 0.0034 for genotypes). CTLA4 þ 49 was not found to be independently associated in this study. All SNPs were found to be in Hardy-Weinberg equilibrium (HWE) after correction for multiple testing except the patient population at CTLA4À658.
We conducted haplotype reconstruction and linkage disequilibrium analysis incorporating all 16 markers in the 2q33 region. This area shows a block of strongly linked SNPs in the ICOS gene, while the remainder of the region appears to form a haplotype extending from the CD28 gene up to and including the ICOS promoter SNPs which is characterised by lower levels of inter SNP LD, an effect which may be maximized by the selection of haplotype tagging markers ( Figure 1 ). Thus, a clear LD boundary exists between the ICOSÀ2119 and ICOS þ 1323 loci. Haplotype analysis was centred on a gene-based, promoter or htSNPs approach. Haplotypes reconstructed from all 16 SNP loci spanning the three genes of interest did not reveal any association with disease. Interestingly, only a comparison of haplotypes constructed from CD28ÀCTLA4À5 0 ICOS markers approached statistical significance for haplotypic frequency differentiation between coeliac cases and controls (Table 3) . Two haplotypes constructed from these markers had frequencies above 5%, one of which (Hap1; GTGTACCAATC) had a significant frequency differential between cases and controls (0.2405 vs 0.3154 respectively; P ¼ 0.035). Analysis of the different regions within this haplotype reveals that haplotypes composed of all CTLA4 markers also show a significant association with disease (Hap2: TACCAA, 0.309 vs 0.349; P ¼ 0.042). Haplotypes composed of the CTLA4 htSNPs or the CTLA4 promoter markers do not show significant association with disease. Haplotypes consisting of the CTLA4 þ 49 and CTLA4_CT60 SNPs only were also investigated, as these have both been widely investigated and proposed to have a functional effect on disease susceptibility. No haplotype reaching significance was observed. No significant associations were observed for CD28, total ICOS, htICOS or ICOS promoter haplotypes (data not shown).
Discussion
The CTLA4 gene has been the focus of much analysis in the effort to map the causative factors of CD, and autoimmune diseases in general in the chromosomal region 2q33. This region, which also contains the immunologically important genes, CD28 and ICOS, has long been associated with autoimmune disease, but the exact causal genetic sequence variation has yet to be established in CD.
Our results show the association of several SNPs in the CTLA4 gene with CD, among them, the functional SNP, CT60, however after stringent correction for multiple testing, only CTLA4À658 remains significant. Furthermore, haplotypes constructed in the region show a larger frequency differential between cases and controls than any individual SNP, with the strongest association defining a haplotype block extending from the 5 0 end of ICOS through CTLA4 and including the most distal gene CD28. 
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Previous studies have resulted in conflicting findings, with no genetic association being consistently reproducible. The conflicting results between the studies investigating the CTLA4 region and CD may be due to a number of factors. For example, there may be genetic heterogeneity between population groups studied, while some other studies may not have had sufficient power to detect a disease locus in the region, as this locus appears to confer only a low genotypic risk to disease. One study 22 has estimated the disease locus in the 2q33 gene region as being associated with, at most, a 1.8-fold increased sibling relative risk of CD, but stated that the real figure is probably closer to 1.3 or less. With a 1.8-fold increased sibling relative risk, a study of 100 affected sibpairs will have less than 35% power to detect a susceptibility locus. The choice of genetic markers in association studies is also a critical factor. 39 Of the 16 SNPs we analysed in this region, only four show independent association with disease status; these are CTLA4À658, CTLA4À1661, CTLA4_CT60 and CD28_rs3769683. CTLA4À658 was the only polymorphsim found to deviate from HWE in the patient population. Such deviation may also suggest a role for the locus in disease susceptibility. 40 Notably, Ueda et al. 36 have comprehensively studied the CD28-CTLA4-ICOS region, identifying 108 SNPs and determined that the highest level of association with a number of autoimmune disorders (CD was not studied) was at CT60 ( þ 6230A/G). They suggested that the CT60 polymorphism influences alternate RNA splicing of CTLA4, resulting in differing ratios of a full-length form, flCTLA4, and a soluble form, sCTLA4, of the protein. Individuals who carry the G allele have a lower proportion of sCTLA4 when compared with those carrying the A allele. sCTLA4 can bind to the CD80/CD86 receptors, competing with CD28 and can inhibit T-cell proliferation; hence, individuals deficient in the soluble form of the protein may experience abnormal T-cell proliferation similar to that seen in autoimmune disease. CT60 is the only variant among those showing a trend towards significance, which has been shown experimentally to have a functional role in gene regulation or protein function.
Most earlier studies of this region have focused on the characterized þ 49, À318 and 3 0 (AT) n polymorphisms in 34 We have utilised the haplotype tagging approach for the CTLA4 gene outlined by Johnson et al., 37 which identified five htSNPs, which we genotyped in our population. We also genotyped CT60, given its potential functional importance. The haplotype frequencies observed in our study were comparable to those seen previously with the exception of the CTLA4 SNP haplotype TACCG comprising sites À1722, À1661, À658, À318 and þ 49 (34.9 vs 24.4% (previous)). This may be in part due to the high frequency of the CTLA4 þ 49G allele in our population and possibly to differing patterns of LD between populations.
Similarly, our work on the ICOS gene involved the genotyping of htSNPs describing haplotypes defined in a European population. 38 Using haplotypes constructed from 16 ICOS SNPs, we identified six htSNPs to tag this variation. Due to genotyping difficulties, we were unable to type ICOS þ 2412, so we could not distinguish between two separate haplotypes with a combined predicted frequency of 40% (35 and 5%). However, none of the identified haplotypes, including this combined pair, showed results even approaching a significant difference between the groups in our population sample, so it is unlikely that this combined haplotype is masking any significant association. The haplotype frequencies seen in our study were again comparable to those observed in previous studies. We also included two SNPs in the ICOS promoter region in addition to the htSNPs. These were included as they may have functional effects on gene expression and they have the added benefit of further defining the ICOS haplotypes. These are the À2394 polymorphism situated in a consensus Sp1 site and the À2119 SNP situated in a 34 which found an association with CD, we conclude that our results do not confirm this association. In this previous analysis, eight polymorphisms were genotyped, of which two polymorphisms overlap with those studied here ( þ 4031 and þ 5291). They found evidence for association with four Chromosome 2q33 candidate genes in coeliac disease K Brophy et al polymorphic sites including þ 4031 (identified as ICOSc.602A/C in their study). We found no evidence for association at this locus. This investigation also found the haplotype containing all four associated SNPs to be more highly associated with disease than the individual SNPs. Using our data and the haplotype information given in their study, we are able to tag this haplotype using the þ 5291 SNP (ICOSc.1862 in previous study) alone, as the associated haplotype is the only one to contain the G allele at this position and thus we conclude that this haplotype is not associated with disease in our population.
Our haplotype analysis of CD28 involved three markers selected from dbSNP, chosen to give coverage of the gene. No conclusive association with disease was observed and this finding is consistent with an earlier pan European study. 35 Analysis of the entire region reveals that the most strongly associated haplotype is coterminous with the previously reported LD structure of the region, 34 which we confirm by pairwise linkage disequilibrium analysis incorporates CD28, CTLA4 and the 5 0 region of ICOS. This shows that SNPs in the coding region of the ICOS gene form part of a haplotype block with high levels of LD. A clear discontinuity exists between ICOS þ 1323 and ICOSÀ2119, separating the ICOS block from another region with relatively high levels of LD centered on the CTLA4 and ICOS promoter SNPs. This does not extend to CD28, so while common haplotypes span this region, it does not constitute a haplotype block per se.
Haplotypes consisting of CTLA4 markers only are less strongly associated with disease status, while CD28 and ICOS haplotypes are not independently associated. Our results are similar to those recently published by Hunt et al., 24 who showed a disease association with the CTLA4 haplotype TCCGG (using CTLA4 markers À1722, À658, À318, þ 49, CT60), whereas we show a protective effect with the core haplotype TCCAA (and extending to neighboring markers in CD28 and 5 0 ICOS). These results implicate the CTLA4 gene as being the most likely of the three candidate genes to be causally associated. On the other hand, the greater magnitude of association when the disease-associated haplotypes spanning all three genes are considered, suggests a number of possible scenarios. For example, other unassayed SNPs that are on, or in LD with these haplotypes, could be the susceptibility variants in this population or specific combinations of known SNPs in the vicinity may be required for susceptibility. CD28, CTLA4 and ICOS interact to regulate T-cell activity. The fact that all or part of these three genes are found on the associated haplotypes allows for the possibility that small levels of genetic variation at any combination of these genes may have an additive effect in perturbing this demonstrably important system.
In conclusion, the association of the CTLA4 region with CD has now been replicated several times. The fact that some studies have failed to detect association may in part be due to the low magnitude of the risk conferred by this region. Heterogeneity in study design compounds the difficulty in making direct comparisons, which should be minimised by the use of haplotype tagging. However, alleles that are associated in some populations (e.g. CTLA4 þ 49A) are clearly not in ours, suggesting that population heterogeneity may be a contributing factor in the conflicting results presented in the literature. Our results suggest that the disease association in this population lies in LD with a specific extended haplotype around CTLA4, strengthening the evidence for the involvement of chromosome 2q33 in CD risk modification.
Materials and methods

Subjects
Samples from 394 unrelated Irish individuals suffering from CD were collected from the Department of Gastroenterology, St James Hospital, Dublin, from the Adelaide and Meath Hospital, Tallaght, Dublin and from the University College Hospital, Galway. Patients were subject to biopsy and diagnosed on the basis of histologic appearance and response to a gluten-free diet. A total of 421 unselected ethnically matched unrelated healthy controls were also collected for a case-control study. Biological samples and clinical data were collected with informed consent and ethical review board approval.
Genotyping
Subjects were genotyped for 16 single-nucleotide polymorphisms in the 2q33 region covering the genes CD28, CTLA4 and ICOS. The CTLA4À1722C/T (rs733618) and CTLA4À1661A/G (rs4553808) polymorphisms were analysed using Taqman technology (Applied Biosystems, Foster city, CA, USA). The CTLA4À1661A/G SNP was assayed using forward primer 5 0 -CTT GAG GGC AGG AAC ATT TGT TTT-3 0 and reverse primer 5 0 -GCC AGA The CD28int3 þ 17C/T (rs3116496), CTLA4À658C/T (rs11571317), CTLA4À318C/T (rs5742909), CTLA4_C-T60A/G (rs3087243) and CTLA4 þ 49A/G (rs231775) polymorphisms were analysed using PCR-restriction fragment length polymorphism (PCR-RFLP) analysis. The CD28int3 þ 17C/T and CTLA4À318C/T polymorphisms were genotyped as previously described. 20, 41 The CTLA4À658C/T polymorphism was amplified using mismatch primers 5 0 -GCT TTT CTT TGG ACC TTC TTC A-3 0 and 5 0 -TCA CAA GAA ATA AAC TGA AAA TAG CC-3 0 designed using the PIRA program 42 and digested with restriction enzyme MspI. The CTLA4_C-T60A/G polymorphism was also amplified using mismatch primers designed in the same way; 5 0 -TTT CTT CAC CAC TAT TTG GGA TAT ACC-3 0 and 5 0 -TAG TTG AGC TGA GAA AGC AGG C-3 0 . The amplified product was digested with restriction enzyme NcoI. The CTLA4 þ 49A/G polymorphism was analysed using primers 5 0 -GAT TCT GTG TGG GTT CAA AC-3 0 and 5 0 -TTG CAG AAG ACA GGG ATG-3 0 and the resulting product was digested using BbvI. Primers were obtained from MWG-Biotech AG, Ebersberg, Germany and enzymes were obtained from New England Biolabs, Ipswich, MA, USA.
The remaining polymorphisms were genotyped using Amplifluor technology and primer sequences are listed in Table 4 .
As a routine quality control, approximately 10% of samples within each assay were retyped anonymously, and three of the Amplifluor assays were retyped using RFLP in order to detect any errors. The CTLA4 þ 49A/G assay was repeated using RFLP and Ampliflour.
Statistical analyses
Allelic and genotypic frequencies were obtained using HITAGENE (http://www.hitagene.com) and also by direct counting. Comparison of frequency differences between patient and control groups was assessed using the w 2 test or Fishers exact test as implemented by HITAGENE and also by calculation on a 2 Â 2 or 2 Â 3 contingency table using the STATCALC program. 43 Global statistics for haplotype associations when gametic phase is ambiguous, were performed by HAPLO.SCORE (Table 3) . 44 Simulated P-values (P sim ) were obtained from 1000 replicates, and haplotypes with a frequency of o0.05 were omitted. Linkage disequilibruim was analysed using D 0 values as generated by HAPLOVIEW 45 and HITAGENE. Correction for multiple testing was performed using permutation testing. For each of 5000 permutations, 394 subjects from the combined case and control populations were randomly labelled 'cases' and the remainder labelled 'controls', thus maintaining the overall genotype structure. Frequency differences in 'cases' and 'controls' were compared for each SNP and the minimum P-values calculated. We then compared the calculated P-values to the lower 5th centile of minimum P-values among the permutations. Permutation analysis was carried out using Stata 8.2. Chromosome 2q33 candidate genes in coeliac disease K Brophy et al
